Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) Equity Average (2020 - 2025)

Legend Biotech filings provide 6 years of Equity Average readings, the most recent being $1.0 billion for Q1 2025.

  • On a quarterly basis, Equity Average fell 14.79% to $1.0 billion in Q1 2025 year-over-year; TTM through Mar 2025 was $1.0 billion, a 14.79% decrease, with the full-year FY2024 number at $1.1 billion, up 14.84% from a year prior.
  • Equity Average hit $1.0 billion in Q1 2025 for Legend Biotech, down from $1.1 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.4 billion in Q3 2023 to a low of $273185.0 in Q2 2021.
  • Median Equity Average over the past 5 years was $1.0 billion (2023), compared with a mean of $833.8 million.
  • Biggest five-year swings in Equity Average: surged 30638.63% in 2021 and later dropped 17.17% in 2024.
  • Legend Biotech's Equity Average stood at $495.9 million in 2021, then skyrocketed by 51.95% to $753.6 million in 2022, then skyrocketed by 71.92% to $1.3 billion in 2023, then fell by 16.76% to $1.1 billion in 2024, then dropped by 4.56% to $1.0 billion in 2025.
  • The last three reported values for Equity Average were $1.0 billion (Q1 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q3 2024) per Business Quant data.